NASDAQ
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Open
$6.30
Previous Close
$6.28
Day High
$6.50
Day Low
$6.16
52 Week High
$9.12
52 Week Low
$3.76
No price data available for this timeframe.